Get the latest news, insights, and market updates on SLNO (Soleno Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Soleno Therapeutics (SLNO) Valuation Check After Wolfe Research’s Optimistic New Coverage and Stock Pop
Soleno Therapeutics (SLNO) is back on traders’ screens after Wolfe Research kicked off coverage with an upbeat view, helping push the stock up about 5% as investors reassess the risk reward setup. See our latest analysis for Soleno Therapeutics. Today’s pop, taking the share price to about $52, builds on a steady upward trend, with a roughly mid teens year to date share price return and an exceptional multi year total shareholder return that signals momentum is still very much alive. If... Dec 15, 2025 - $SLNO
How Soleno Therapeutics' Audit Committee Leadership Transition At Soleno Therapeutics (SLNO) Has Changed Its Investment Story
Earlier this month, Soleno Therapeutics announced the passing of long-time board member and Audit Committee Chair William G. Harris, while indicating that experienced director Andrew Sinclair, recognized as an “audit committee financial expert,” is expected to assume the committee chair role. Harris’ decades of finance leadership across several biopharmaceutical companies, combined with Sinclair’s regulatory and accounting credentials, highlight how governance continuity remains a priority... Dec 15, 2025 - $SLNO
Is Soleno Therapeutics, Inc. (SLNO) The Cheap Healthcare Stock To Buy Heading Into 2026?
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Soleno Therapeutics, Inc. (NASDAQ:SLNO) has a consensus Buy rating, as all 13 analysts covering the stock have assigned a ‘Buy’ or equivalent rating. With a median price of $110, the stock boasts an upside potential of […] Dec 10, 2025 - $SLNO
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to announce the passing of William G. “Bill” Harris, who served as a valued member of Soleno’s Board of Directors since June 2014. Mr. Harris also served as Chairman of the Audit Committee. “I have known Bill for many years, and always viewed him as a person of integrity, who exhibite Dec 3, 2025 - $SLNO
Soleno Therapeutics (SLNO): Does Current Valuation Signal Opportunity or Caution for Investors?
Soleno Therapeutics (SLNO) has seen its stock price swing in recent weeks, catching the attention of investors looking for value and momentum. The company focuses on treatments for rare diseases, which often draws keen interest from the biotech community. See our latest analysis for Soleno Therapeutics. Soleno’s share price has been on a volatile run lately, with strong short-term swings: up nearly 12% for the week, but still down around 25% over the past three months. Despite recent... Dec 1, 2025 - $SLNO
Analyst Dismisses ViCAT XR Safety Fears, Expects Strong Growth Despite Recent Stock Weakness
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best upside stocks to buy now. On November 18, Wolfe Research analyst Kalpit Patel initiated coverage of Soleno Therapeutics with an Outperform rating and $75 price target. The stock price has been weak recently due to a sequential slowdown in the number of new patients starting treatment […] Nov 30, 2025 - $SLNO
Could Soleno Therapeutics Have Room to Run After FDA Designation Sparks 11.8% Rally?
Curious whether Soleno Therapeutics is a hidden gem or already overhyped? You're not alone, and now is the perfect time to take a closer look at what the numbers suggest about its value. The stock has been on a wild ride lately, jumping 11.8% in the past week, but still down 24.9% over the last month. Yet it remains up 10.4% year-to-date and has delivered a staggering 4846.1% return over three years. Recent headlines highlighting the company’s progress on rare disease therapeutics and... Nov 30, 2025 - $SLNO
Soleno Therapeutics (SLNO) Reports Strong Q3 Earnings Despite VYKAT XR Safety Concerns
Soleno Therapeutics, Inc. (NASDAQ:SLNO) ranks among the most oversold biotech stocks to invest in. Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported third-quarter adjusted earnings of $0.47 per share on November 4, significantly exceeding analyst projections of $0.05 per share. Revenue also came in significantly higher than the consensus expectations at $66 million. Despite the strong results, the […] Nov 25, 2025 - $SLNO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple